2012-10-10 09:17:52 - New Pharmaceuticals market report from Global Markets Direct: "Biotest AG - Product Pipeline Review - 2012"

Global Market Direct's pharmaceuticals report, "Biotest AG - Product Pipeline Review - 2012" provides data on the Biotest AG's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Biotest AG's corporate website, SEC filings, investor presentations and featured press releases, both from Biotest AG and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

* Biotest AG - Brief Biotest AG overview including business description, key information and facts, and its locations and subsidiaries.
* Review of current pipeline of Biotest AG human therapeutic division.
* Overview of pipeline therapeutics

across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of Biotest AG with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the Biotest AG's pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.


Full Report Details at
- www.fastmr.com/prod/468514_biotest_ag_product_pipeline_review_20 ..


Reasons to buy

* Evaluate Biotest AG's strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of Biotest AG in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the Biotest AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with Biotest AG.
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of Biotest AG and identify potential opportunities in those areas.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Biotest AG Snapshot
Biotest AG Overview
Key Information
Key Facts
Biotest AG - Research and Development Overview
Key Therapeutic Areas
Biotest AG - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Biotest AG - Pipeline Products Glance
Biotest AG Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Biotest AG - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Biotest AG - Drug Profiles
BT-061 + Methotrexate
Product Description
Mechanism of Action
R&D Progress
BT-062
Product Description
Mechanism of Action
R&D Progress
BT-063
Product Description
Mechanism of Action
R&D Progress
tregalizumab
Product Description
Mechanism of Action
R&D Progress
Biotest AG - Pipeline Products by Route of Administration
Biotest AG - Pipeline Products By Mechanism of Action
Biotest AG - Recent Pipeline Updates
Biotest AG - Dormant Projects
Biotest AG - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Civacir
Biotest AG - Company Statement
Biotest AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Biotest AG - Key Manufacturing Facilities
Biotest AG, Recent Developments
Biotest AG- Press Release
Dec 07, 2009: Immunoconjugate BT-062 Shows First Data Of Clinical Efficacy
Oct 20, 2009: Biotest AG Announces, Monoclonal Antibody BT-061 Shows Efficacy In Patients With Rheumatoid Arthritis
Sep 30, 2009: Biotest AG Announces Initiation Of Clinical development Of BT-063
Feb 19, 2009: Tarix Recruits First Patient For Phase II Study To Mitigate Chemotherapy-Induced Thrombocytopenia
Financial Deals Landscape
Biotest AG, Deals Summary
Biotest AG, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Biotest Acquires Plasmapheresis Centre In US From Talecris
Biotest Acquires Biologics Business Unit From Nabi BioPharma
Partnerships
Abbott Labs Enters Into Co-Development Agreement With Biotest For BT-061
Biotest Enters Into Research Collaboration With Johannes Gutenberg University
Olympus America Enters Into An Agreement With Biotest
Biotest Enters Into Joint Venture With Sanquin
Licensing Agreements
ImmunoGen Enters Into Licensing Agreement With Biotest
Equity Offering
Biotest Completes Private Placement Of $27.49 Million
Biotest Completes Private Placement Of $18.97 Million
Acquisition
Merck Acquires heipha Dr. Muller And Related Assets From Biotest
Bio-Rad Labs Completes Acquisition Of Medical Diagnostics Segment From Biotest
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Biotest AG, Key Information
Biotest AG, Key Facts
Biotest AG - Pipeline by Indication, 2012
Biotest AG - Pipeline by Stage of Development, 2012
Biotest AG - Monotherapy Products in Pipeline, 2012
Biotest AG - Combination Treatment Modalities in Pipeline, 2012

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468514&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.